Cision PR Newswire, Author at World Lifestyler

No Result

View All Result

WORLD LIFESTYLER

No Result

View All Result

Home Author

Cision PR Newswire

Press Releases - Lifestyle

Once-Weekly CagriSema (Amylin-Semaglutide) Combination Injection More Effective than Standalone Medications

June 7, 2026

Press Releases - Lifestyle

Novo Nordisk’s CagriSema 2.4 mg / 2.4 mg demonstrated significant reduction in HbA1c and weight across multiple studies in the REIMAGINE program presented at ADA 2026

June 7, 2026

Press Releases - Lifestyle

AMGEN PRESENTS NEW DATA ACROSS ITS CARDIOMETABOLIC PORTFOLIO AT AMERICAN DIABETES ASSOCIATION 86TH SCIENTIFIC SESSIONS

June 7, 2026

Press Releases - Lifestyle

Lipid-Lowering Medications Demonstrate Cardiometabolic Benefits in Populations with High-Risk Diabetes

June 7, 2026

Press Releases - Lifestyle

Once-Weekly Drug Demonstrates Promising Dual Benefits in Obesity and Metabolic Health

June 7, 2026

Press Releases - Lifestyle

Head-to-head Study Validates the Clinical Advantage of New-generation Biased GLP-1: Ecnoglutide Delivers 35% Greater Weight Loss than Semaglutide

June 7, 2026

Press Releases - Lifestyle

Bronstein, Gewirtz & Grossman LLC Urges Badger Meter, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

June 7, 2026

Press Releases - Lifestyle

Bronstein, Gewirtz & Grossman LLC Urges GeneDx Holdings Corp. Investors to Act: Class Action Filed Alleging Investor Harm

June 7, 2026

Press Releases - Lifestyle

Lilly’s Foundayo (orforglipron), the only oral GLP-1 taken without food or water restrictions, was associated with significant weight loss in women at every stage of menopause

June 7, 2026

Press Releases - Lifestyle

RGC Deadline: RGC Investors with Losses in Excess of $100K Have Opportunity to Lead Regencell Bioscience Holdings Limited Securities Fraud Lawsuit

June 7, 2026

Page 778 of 3689 Prev 1 … 777 778 779 … 3,689 Next

No Result

View All Result

Home

Cision PR Newswire

Once-Weekly CagriSema (Amylin-Semaglutide) Combination Injection More Effective than Standalone Medications

Novo Nordisk’s CagriSema 2.4 mg / 2.4 mg demonstrated significant reduction in HbA1c and weight across multiple studies in the REIMAGINE program presented at ADA 2026

AMGEN PRESENTS NEW DATA ACROSS ITS CARDIOMETABOLIC PORTFOLIO AT AMERICAN DIABETES ASSOCIATION 86TH SCIENTIFIC SESSIONS

Lipid-Lowering Medications Demonstrate Cardiometabolic Benefits in Populations with High-Risk Diabetes

Once-Weekly Drug Demonstrates Promising Dual Benefits in Obesity and Metabolic Health

Head-to-head Study Validates the Clinical Advantage of New-generation Biased GLP-1: Ecnoglutide Delivers 35% Greater Weight Loss than Semaglutide

Bronstein, Gewirtz & Grossman LLC Urges Badger Meter, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

Bronstein, Gewirtz & Grossman LLC Urges GeneDx Holdings Corp. Investors to Act: Class Action Filed Alleging Investor Harm

Lilly’s Foundayo (orforglipron), the only oral GLP-1 taken without food or water restrictions, was associated with significant weight loss in women at every stage of menopause

RGC Deadline: RGC Investors with Losses in Excess of $100K Have Opportunity to Lead Regencell Bioscience Holdings Limited Securities Fraud Lawsuit

Recommended

BLUETTI Wins EUPD Research “Top Innovation Award 2026” in Europe

IFPA and WHO Foundation launch a strategic collaboration to strengthen global psoriasis care

Popular News

MSC Income Fund Announces Second Quarter 2026 Earnings Release and Conference Call Schedule

Solstice Advanced Materials Declares Dividend of $0.075 per Common Share

Bluon and WEX® Announce Strategic Agreement to Empower HVAC and Plumbing Contractors Nationwide

REGENXBIO Announces Pricing of Public Offering of Common Stock and Pre-funded Warrants

Pudu Robotics Highlights Its “One Brain, Multiple Embodiments” Physical Agent at WAIC 2026

Connect with us

About & Contact

Explore Content

Legal & Privacy

Tiny Media Brands